Loading cancer entity…
Subtype
CI-CAN-00002836HNSCC · SCCHNExplore in graph →
Clinical trials
1,589 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (247)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05057247 | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | completed | Phase 2 | 26 | Kartik Sehgal, MDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT07831083 |
| Skin Cancer Among Outdoor Workers(Skin Cancer Am) |
| completed |
| — |
| 10,000 |
| Assuta Medical CenterOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT05249426 | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT06236425 | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04868162 | A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | completed | Phase 2 | 70 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05816785 | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer | completed | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07802977 | Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia | completed | Phase 1 | 10 | University of California, DavisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05909904 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 160 | BeiGeneINDUSTRY | 14 | Sep 1, 2026 | clinicaltrials |
| NCT05935995 | Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination(HISTOBLOC) | completed | N/A | 42 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT04943445 | Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers(SMART-KEY) | completed | Phase 2 | 43 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07778615 | Immunohistochemical Expression of Cyclin D1 in Oral Squamous Cell Carcinoma: Relationship With Clinicodemographic and Histopathological Features | completed | — | 34 | Sohag UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT03650764 | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Washington University School of MedicineOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06251050 | A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy | completed | Phase 1 / Phase 2 | 175 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04354246 | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies | completed | Phase 1 | 94 | Compugen LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06289049 | Heavy Strength Training in Head and Neck Cancer Survivors(LIFTING2) | completed | Phase 2 | 37 | University of AlbertaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05119036 | Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma | completed | N/A | 82 | Indiana UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT02296684 | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 67 | Washington University School of MedicineOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04290546 | CIML NK Cell in Head & Neck Cancer | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06307093 | Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | completed | Phase 1 | 90 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 | clinicaltrials |
| NCT04609566 | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | completed | Phase 2 | 161 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07682285 | Taiwanese Green Propolis for Lipid Profiles, Fatigue, and Quality of Life in Oral Cavity Cancer Survivors(TGP-OCS) | completed | N/A | 25 | Taipei Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01772706 | Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer(LaserMucite) | completed | N/A | 97 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07040956 | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients. | completed | Phase 2 | 98 | West China HospitalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06366451 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC | completed | Early Phase 1 | 17 | Presage BiosciencesINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07670403 | Digital Phenotyping of Psychological Distress in Skin Cancer Patients(DP-SKIN) | completed | — | 500 | West China HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05721443 | Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC | completed | Phase 2 | 28 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04603248 | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | completed | N/A | 50 | Yonsei UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03838601 | Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2(ROMA LA-OPSCC2) | completed | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04733495 | Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment | completed | N/A | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04847466 | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05294900 | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients(NEOS) | completed | Phase 2 | 79 | Yonsei UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | completed | Phase 2 | 316 | NRG OncologyOTHER | 4 | May 22, 2026 | clinicaltrials |
| NCT03336606 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05278039 | Training Swallowing Initiation During Expiration | completed | N/A | 88 | Northwestern UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02841748 | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | completed | Phase 2 | 100 | University of ChicagoOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04369937 | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 18 | Dan ZandbergOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04665843 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck(SKYSCRAPER-09) | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY | 13 | May 5, 2026 | clinicaltrials |
Data updated 14 hours agoSource updated Sep 29, 2026source: clinicaltrials